Skip to content

Peptide Therapy

Peptides for Muscle Growth and Body Composition

Muscle and body-composition peptides come up when someone wants more than weight loss: better lean mass, lower visceral fat, stronger recovery, a sharper training response, or a more youthful body-composition profile.

Most of the conversation centers on growth-hormone signaling, insulin-like growth factor 1, and whether the peptide sits inside a real training plan or is carrying the body-composition story on its own.

Reading time
4 min
Source last reviewed
12 May 2026
Last updated
12 May 2026

Reader compass

What to sort first

01

The body-composition goal

Lean mass, visceral fat, strength, recovery, and appearance are different targets and shouldn't be measured the same way.

02

The peptide pathway

Sermorelin, ipamorelin, CJC-1295, tesamorelin, and related products act through different growth-hormone or growth-hormone-adjacent pathways.

03

The training plan

A body-composition peptide should sit beside resistance training, protein, sleep, and measurement, not replace them.

The appeal is easy to understand. Muscle is central to longevity. It protects function, glucose disposal, mobility, independence, and the ability to train hard enough to keep adapting.

Visceral fat matters too, because it's closely tied to cardiometabolic risk.

That's why peptides aimed at growth hormone, recovery, and body composition get attention. People aren't only chasing a lower number on the scale.

They want a body that performs, recovers, and ages better.

The practical question is what the peptide is supposed to do. Stimulate growth-hormone signaling? Shift visceral fat? Support a medically defined deficiency? Improve recovery enough to train better?

Each version needs its own plan.

The main peptide categories

Most muscle and body-composition peptide protocols sort into a few categories.

Decision table 01
CategoryCommon examplesWhat people are usually pursuing
Growth-hormone releasing hormone analogsSermorelin, CJC-1295, tesamorelin.Growth-hormone signaling, IGF-1 changes, recovery, sleep, body-composition goals.
Growth-hormone secretagoguesIpamorelin and related secretagogues.A pulse-like growth-hormone signal, often discussed for recovery and body composition.
Visceral-fat protocolsTesamorelin in its studied medical use.Reduction of excess abdominal or visceral fat in a defined clinical population.
Repair-adjacent protocolsBPC-157, TB-500, and similar products.Training continuity, soft-tissue recovery, and return to movement rather than direct muscle growth.
Metabolic peptidesGLP-1s and dual incretin medications.Fat loss, appetite control, and metabolic-risk improvement, with muscle preservation as part of the plan.

IGF-1 stands for insulin-like growth factor 1. It's one of the main blood markers clinicians use to evaluate growth-hormone activity.

It isn't a muscle score by itself, but it helps show whether a growth-hormone-axis protocol is moving the biology it's meant to move.

What the protocol looks like

A body-composition peptide plan should look like a measured training protocol, not just a vial.

The core pieces are straightforward:

  • body-composition baseline.
  • resistance-training plan.
  • protein and calorie plan.
  • sleep and recovery context.
  • peptide name, route, dose, and source.
  • IGF-1 and relevant safety labs when growth-hormone signaling is involved.
  • strength, waist, weight, and function tracking.
  • a follow-up point to adjust or stop.

Where the evidence is stronger

Growth-hormone signaling can change body composition, but the details matter.

Reviews of growth-hormone secretagogues describe their ability to raise growth-hormone signaling and the potential relevance to lean mass, fat mass, exercise tolerance, and body composition, while also stressing safety and the need for context 1.

Human data on direct growth-hormone treatment in older adults show why body-composition claims need careful interpretation.

Some trials reported increased lean body mass or improved body composition, but functional outcomes didn't always follow and side effects occurred 2 3.

Tesamorelin is the clearest example of a peptide with a defined body-composition use. It's a growth-hormone-releasing factor analog studied and used for reducing excess abdominal fat in HIV-associated lipodystrophy.

Reviews and trials describe reductions in visceral fat and body-composition effects in that population 4 5.

That doesn't make tesamorelin a general fat-loss peptide for everyone. It means a peptide can have real body-composition evidence inside a specific clinical setting.

Decision table 02
ClaimEvidence statusHow to read it
Increase IGF-1Established (for some growth-hormone-axis peptides)A biological change, not proof of better muscle or longevity by itself.
Reduce visceral fatEstablished (tesamorelin, defined clinical population)Don't generalize the indication to every body-composition goal.
Increase lean massEmerging (by product and population)Lean mass changes should be paired with strength and function.
Improve strengthDebatedTraining program and measured performance matter more than peptide claims.
Improve appearanceInsufficient evidenceStill being studied; use waist, photos, DEXA, and body-composition tracking rather than vague visual claims.

How to make the plan useful

The peptide shouldn't carry the whole protocol. It should support a plan that already makes sense.

  1. Define the target

    Choose the target: lean mass, visceral fat, strength, recovery, appearance, or metabolic risk.

  2. Measure the baseline

    Use weight, waist, strength, training history, labs, and DEXA when body-composition detail would change the plan.

  3. Build around training

    Resistance training, protein, calories, sleep, and progressive overload remain the foundation.

  4. Track the growth-hormone axis

    When the protocol targets growth-hormone signaling, IGF-1 and metabolic safety markers help keep the plan grounded.

The cleanest version sounds simple: "I'm using this protocol to support a measured body-composition goal while I train, eat enough protein, sleep, and track whether strength and lean mass are improving."

If there's no training plan, the peptide is carrying too much of the story.

Safety and fit

Growth-hormone-axis peptides can pull on IGF-1, glucose, fluid retention, joint symptoms, carpal-tunnel-like symptoms, sleep, appetite, and other hormone pathways.

They may not fit people with active cancer, a history of certain cancers, uncontrolled diabetes, significant insulin resistance, severe sleep apnea, edema, complex endocrine disease, or several medications running at once without clinician oversight.

Source and route matter. Injectable peptides raise questions about sterility, storage, potency, reconstitution, injection technique, and pharmacy.

A provider should be able to explain why the peptide fits the goal and what would lead to a dose change or a stop.

Where these peptides fit in a longevity plan

Muscle and body composition are central longevity targets. Peptides may support the plan in selected contexts, but the foundation is still resistance training, protein, sleep, cardiometabolic health, and measurement.

DEXA body composition is the most relevant companion test for lean mass, fat mass, or visceral-fat context. VO2 max testing helps keep fitness separate from appearance.

Testosterone replacement therapy and thyroid optimization cover endocrine decisions that can overlap with strength, weight, and body composition.

The best peptide protocol for body composition is specific enough to measure.

Name the goal, train for it, track body-composition changes, monitor the growth-hormone axis when relevant, and decide ahead of time what would make the plan worth continuing.

Sources and references
  1. 1

    Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sexual Medicine Reviews. 2018. PMC ↑

  2. 2

    Papadakis MA, Grady D, Black D, et al. "Growth hormone replacement in healthy older men improves body composition but not functional ability." Annals of Internal Medicine. 1996. PubMed ↑

  3. 3

    Liu H, Bravata DM, Olkin I, et al. "Systematic review: the safety and efficacy of growth hormone in the healthy elderly." Annals of Internal Medicine. 2007. PubMed ↑

  4. 4

    Dhillon S. "Spotlight on tesamorelin in HIV-associated lipodystrophy." BioDrugs. 2011. PubMed ↑

  5. 5

    Stanley TL, Feldpausch MN, Oh J, et al. "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation." JAMA. 2014. JAMA ↑

  6. 6

    U.S. Food and Drug Administration. "Tesamorelin for injection, full prescribing information." 2025. FDA ↑

  7. 7

    U.S. Food and Drug Administration. Federal Register notice on sermorelin acetate injection not withdrawn from sale for reasons of safety or effectiveness (78 FR 14095). 2013. Federal Register ↑

  8. 8

    U.S. Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act." Updated May 14, 2026. Accessed September 2026. FDA ↑

  9. 9

    U.S. Food and Drug Administration. "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." 2026. Accessed September 2026. FDA ↑

  10. 10

    Ravitz JR, et al. "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting." McDermott Will & Schulte. 2026. McDermott ↑

  11. 11

    World Anti-Doping Agency. "The Prohibited List." 2026. Accessed September 2026. WADA ↑

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint